• 1-(844)-30-STOCK

Need updates On Your Mobile Text STOCKS to 67076

Why ISR


Date : May 15, 2018

The ISR Breakout: Is the Company’s Revolutionary Treatment Ready to Take Over?

New Opportunity:  IsoRay Inc. (NYSE American: ISR)

Today’s newest idea is a company that is pursuing a potentially disruptive cancer treatment using Cesium-131, a cancer fighting isotope that is currently used to treat a broad range of cancers. The company’s primary focus at present is Prostrate Cancer – a treatment market valued at $5.63B in 2016, but expected to reach $18.4B by 2025.

However, the company’s unique and promising “Cesium-131 brachytherapy” approach is expected to expand into the treatment of both brain and head and neck cancers before long.

This is a company has begun to show not only leading tech, but also an ability to post serious and sustained top line revenue growth. And the chart makes it awfully clear the stock is starting to spark some major interest, with a recent glaring breakout above major moving averages on some serious volume.

The early money is finding this one, but there’s still time to get on board ahead of the crowd… if you move fast!

Symbol:  ISR

Company:  IsoRay Inc.

Quote:  http://finance.yahoo.com/q?s=ISR

Latest News:  http://finance.yahoo.com/q/h?s=ISR+Headlines

Who is ISR

isr stock aert

Who is ISR

IsoRay, Inc., through its subsidiary, IsoRay Medical, Inc., develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States. The company produces CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers, as well as ocular melanoma.

It sells its products to facilities or physician practices that utilize multiple surgical facilities at which primarily prostate brachytherapy procedures are performed. The company was formerly known as Century Park Pictures Corporation and changed its name to IsoRay, Inc. in 2005. IsoRay, Inc. was founded in 1983 and is based in Richland, Washington.

IsoRay, Inc., through its subsidiary, IsoRay Medical, Inc. is the sole producer of Cesium-131 brachytherapy seeds, which are expanding brachytherapy options throughout the body.

In other words, Cesium-131 is not a new concept in targeting cancers.

This company has been working on this unique solution for well over a decade. In fact, in that time, the technology involved here has been aimed at helping over 10,000 folks suffering from cancer related issues.

We’ve seen results targeting all sorts of different forms of cancer, and so far, the Cesium-131 isotope has continued to show promise and results. According to company materials, this is something that could eventually supplant other treatment options and take over the market as a leading treatment. And not just in the $18.5B prostate cancer market: the company plans to move forcefully into the brain cancer and head and neck cancer markets next.

isr stock
ISR

Recent Catalysts

In addition to generally pushing forward with its existing legacy flagship Cesium-131 product offering, the company is also clearly pushing forward to up its game – another signal we love to see.

Indeed, the company just announced the upcoming release of its Build-Blu delivery system for real-time prostate brachytherapy.

According to the release, the Build-Blu delivery system is a disposable, next-generation, seed stranding device that will allow prostate brachytherapists to affordably build custom-configured strands with Cesium-131 in the operating room, thereby allowing clinicians to individualize the procedure to the patient’s anatomy in real time. “This new product will provide an alternative solution to the approximately 25% of treatment facilities for the prostate market that are using intra-operative techniques.”

In addition, the company also just reported fresh financial data: Revenue for the third quarter of fiscal 2018 was $1.57 million, a 23% increase compared to revenue of $1.28 million for the third quarter of fiscal 2017 and a 2% increase compared to revenue of $1.54 million in the second quarter of fiscal 2018.

ISR

n other words, not only is this a revenue producing cancer therapy play, but revs are growing on BOTH an annual and sequential basis, which is an extremely important signal for the market.

According to management, the revenue increase was driven by the deepening traction of the Company’s new sales and marketing initiatives, launched 18 months ago, combined with the increasing effectiveness of the new sales team. Prostate brachytherapy represented 83% of total revenue for the third quarter of fiscal 2018 compared to 88% for the third quarter of fiscal 2017. Growing use of IsoRay’s exclusive Cesium-131 isotope in other cancers, such as brain, head and neck, and gynecological, among others, accounted for the difference.

best stock

Technical Analysis

The chart is quite interesting at this point. Obviously, the most interesting feature is the recent massive breakout. It’s hard to miss: the stock just blasted off, breaking above the 50-day and 200-day simple moving averages on a steep increase in trading volume, showing a large new cohort of market participants apparently contributing to the move.

This is exactly what we look for to identify an influx of big-money investors.

In the biosciences, there’s often a much more distinct line between the smart money and the crowd. This is a research-based field. Therefore the smart money is working on hard data with expert consultants. That means, when you see something big happening, it’s often signaled by a big jump in volume, just as we see here, . There are generally far fewer head fakes where this type of phenomenon is concerned in the bioscience area of the market.

That’s why we’re taking this breakout to heart. This could potentially be a special opportunity, as the stock powers above its recent trading range.

ISR.Chart

About ISR

ISR (IsoRay Inc.), through its subsidiary, IsoRay Medical, Inc., develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States. The company produces CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers, as well as ocular melanoma.

It sells its products to facilities or physician practices that utilize multiple surgical facilities at which primarily prostate brachytherapy procedures are performed. The company was formerly known as Century Park Pictures Corporation and changed its name to IsoRay, Inc. in 2005. IsoRay, Inc. was founded in 1983 and is based in Richland, Washington.

IsoRay, Inc., through its subsidiary, IsoRay Medical, Inc. is the sole producer of Cesium-131 brachytherapy seeds, which are expanding brachytherapy options throughout the body.

isr trending stocks

Key Themes:

  • ISR just announced the imminent release of its new and revolutionary Build-Blu product offering, which stands to reshape the Cesium-131 game once again.
  • ISR also just hit the market with new financial data featuring an acceleration in revenue growth, with the y/y rate increasing from 23% to 28%.
  • ISR is making real money, with trailing revs already coming in at $5.7M.
  • ISR just broke out above its 50-day and 200-day SMA’s on a major jump in volume.
  • ISR is coming off an RSI trough under 40, pointing to a massively oversold stock now firmly back in aggressive momentum mode to the upside.

Conclusion

In short, ISR could be a true game changer in a market space projected to be worth nearly $20 billion just a few years down the road.

The company’s technology represents a potential new path forward, and the question is whether or not investors will pay up and chase the idea as it starts to show clear results. According to our research, it looks like the signs are possibly in place where both the results and the chasing money are concerned.

At this point, this is still early days in what may well potentially be a new and emerging trend in the stock following its massive recent breakout higher. Now is the chance to get this one ahead of the crowd.

Disclaimer :

We do not advise any reader take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Our website and newsletter are for entertainment purposes only. MyBestStockPicks engaged in the business of marketing and advertising companies. All content on our website is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Neither the information presented nor any statement or expression of opinion, or any other matter herein, directly or indirectly constitutes a solicitation of the purchase or sale of any securities. Neither the owner of Our Newsletter nor any of its members, officers, directors, contractors or employees are licensed broker-dealers, account representatives, market makers, investment bankers, investment advisors, analyst or underwriters. Investing in securities, including the securities of those companies profiled or discussed on this website is for individuals tolerant of high risks. Never invest purely based on our alerts. Gains mentioned in our newsletter and on our website may be based on end-of-day or intraday data. This publication and their owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. If we own any shares we will list the information relevant to the stock and number of shares here. Mybeststockpicks owns no shares of any of the companies mentioned here within, nor intends to buy any in the future. Mybeststockpicks has been compensated total of two thousand dollars by ALG Financial to perform 1 week investors awareness advertisement on ISR

Total Views: 728 ,